Skip to content 
AMM 317: Sculptra by Galderma: 25 Years of Regenerative Innovation
January 06, 2025
This episode highlights the 25th anniversary of Sculptra®, a pioneering regenerative biostimulator by Galderma, and its impact on aesthetic medicine. Listeners will learn about the journey of Sculptra from its initial use for AIDS patients to becoming a key player in regenerative aesthetics by enhancing collagen and elastin production. The discussion includes its recent approval in the growing Chinese market and new efficacy data, presenting its capabilities in reducing cheek wrinkles and providing lasting results. The episode underscores Galderma’s commitment to addressing diverse aesthetic needs globally.
Quick Takes
- Sculptra® is celebrating its 25th anniversary as the first proven regenerative biostimulator in aesthetic medicine.
- Sculptra, initially approved as a volume replenishment treatment for AIDS patients, has revolutionized regenerative aesthetics through its poly-L-lactic acid formulation that enhances collagen and elastin production in the body.
- Recently approved in China, Sculptra continues to expand its global reach and has shown efficacy in reducing cheek wrinkles with results lasting up to 12 months, leading to high patient satisfaction.
Episode Transcript
Today, January 6th, marks an impressive milestone in the world of aesthetic medicine. Sculptra®, the first proven regenerative biostimulator from Galderma, is celebrating its 25th anniversary. Initially approved as a volume replenishment treatment for AIDS patients in 1999, Sculptra has transformed the field of regenerative aesthetics with its unique poly-L-lactic acid formulation. The treatment stimulates the body’s natural processes to enhance collagen and elastin production, offering long-lasting rejuvenation and volume restoration.
Highlighting its expanding global reach, Sculptra has recently been approved in China, a rapidly growing market for aesthetics. This milestone underscores Galderma’s commitment to meeting diverse needs worldwide, and the new data presented at the American Society for Dermatologic Surgery Annual Meeting only reinforce its efficacy. Studies have shown Sculptra not only significantly reduces cheek wrinkles but also yields results lasting up to 12 months, with a striking 84% of patients expressing high satisfaction with their natural-looking results. As Galderma continues to innovate in skin sciences, Sculptra stands as a testament to the promise of regenerative aesthetics.
Speaking of celebrations, I have a special invitation for you. Please join me for the Canadian Aesthetics Congress in Vancouver from June 7-9, 2024! This is your chance to connect with leaders in aesthetic medicine. And you can get $375 off the registration by using my special code, drfisher-cbam, at checkout. Don’t miss this incredible opportunity and I’ll see you there!
